Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New tweet on Tokens .com https://twitter.com/tokens_com
To me, it's the money tree and the eyes are like the all-seeing eye that is on the backside of the one-dollar bill , just the beginning here .
A tweet from CEO https://mobile.twitter.com/nanotechcrypto
Another CEO interview explains Metaverse and its Trillion-dollar opportunity
Breaking News: Tune in to @CNN
Monday morning at 9:40am EST to catch up with http://Tokens.com CEO, @AndrewKiguel
! $COIN.n $SMURF
$VNTH When the news outlets like CNN, CNBC, and so on find out about our Mr. Kittle being a young Metaverse entrepreneur and a genius and the youngest CEO of a company VNTH, he will be interviewed like crazy , this will give the stock a giant boost in share value and many gamers will come aboard. 2022 will be very good for Metaverse stocks.
NEWS -- Tokens.com & SuperWorld to Form Strategic Metaverse Partnership
TORONTO, January 12, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), and Non-Fungible Tokens ("NFTs"), is pleased to announce that its subsidiary, Metaverse Group, has entered a strategic partnership agreement with SuperWorld to invest up to $ 1 million in virtual real estate on the SuperWorld platform.
SuperWorld is a virtual world in augmented reality (AR), digitally mapped over the surface of the Earth. Plots of SuperWorld land are represented as non-fungible tokens corresponding to real world space. Any user in SuperWorld can explore and create AR content, engage in a virtual real estate marketplace, or buy and sell NFTs in the SuperWorld NFT Salon.
"We are pleased to partner with SuperWorld and bring a greater selection of rental opportunities to businesses seeking to enter the metaverse. This purchase expands our eight figure virtual holdings and bolsters our ability to grow a significant presence as leading virtual landlords," said Andrew Kiguel, CEO, Tokens.com. "Tokens.com is one of the only companies providing public market investors with exposure to the metaverse."
The investment will be used to purchase plots of virtual land in SuperWorld, including virtual duplicates of popular real-world landmark locations, in which upcoming creative projects and events will be hosted by Metaverse Group. More announcements about these projects will be announced by Tokens.com, Metaverse Group and SuperWorld in the coming weeks. This will bring a larger brand marketing opportunity for businesses looking to enter the metaverse. SuperWorld Co-Founder & CEO Hrish Lotlikar stated, "I’m thrilled that SuperWorld will be partnering with the Metaverse Group and Tokens.com to leverage their world-class portfolio and create opportunities in the Metaverse to accelerate our vision of using AR/VR, AI, and blockchain technologies to build a better world."
In addition, Decentraland, one of the leading metaverses, has partnered with Tokens.com for a first of its kind digital fashion show featuring avatar models, catwalks, pop up shops, and immersive experiences. The show is scheduled to take place March 24th to 27th on Tokens.com’s Fashion District Estate.
About Tokens.com
Tokens.com Corp is a publicly traded company that owns an inventory of Metaverse, DeFi and NFT based digital assets. Through a process called staking, Tokens.com’s inventory of crypto assets are used to earn additional tokens. In addition, Tokens.com is the majority owner of the Metaverse Group, one of the world’s first virtual real estate companies. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web 3.0.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.io
About SuperWorld
The SuperWorld virtual real estate platform is mapped over the entire surface of the globe, allowing users to purchase —literally—any place on Earth. From skyscrapers and stadiums to historical monuments and iconic structures including wonders of the natural world, when you step into SuperWorld, you’ll truly make a world of your own.
For further information please visit: https://www.superworldapp.com/
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005615/en/
Contacts
For further information, please contact:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110
Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising new preclinical data regarding PTX-35 has been accepted for publication in the American Journal of Transplantation and is available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.16940.
Key Findings:
SMURF CEO on CNBC $$$$$ https://www.cnbc.com/video/2022/01/10/investors-pay-millions-for-real-estate-in
NEWS -- Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
SAN DIEGO, Calif. and CALGARY, AB, Jan. 11, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
To the Shareholders of Oncolytics Biotech,
2021 generated ground-breaking data that creates the foundation for continued success in 2022 as we build our clinical opportunities and the data required to embark on our registrational study in metastatic breast cancer. This critical data encompasses data requested by the FDA and our global pharma collaborators, data that de-risks both our registrational program and clinical studies going forward. I would like to provide a summary of our 2021 accomplishments, an update on the final pieces of our metastatic HR+/HER2- breast cancer program, and provide some commentary on several of our promising programs in other indications.
Most importantly, the AWARE-1 study results presented this past year exceeded our expectations and provided us with additional confidence in our overall clinical development program. We are well on our way to completing enrollment in BRACELET-1, expected to occur in early 2022. The combination of clinical data from BRACELET-1 along with data from AWARE-1 will provide the final elements necessary to develop and launch a registrational study in metastatic breast cancer.
HR+/HER2- Breast Cancer Program: Our Primary Focus
If you have been following the Company, you're likely aware that we saw a near doubling of overall survival (OS) in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213, a randomized phase 2 study (https://www.oncolyticsbiotech.com/press-releases/detail/33/oncolytics-biotech-inc-s-reolysin-more-than-doubles). After analyzing these data, we focused on achieving three key objectives set forth by regulators and our pharma partners, which represent important steps on the path to a registrational study. These objectives are to:
The good part about SMURF is that 56 million shares are in the float and of that float, 43% is held by insiders and institutions. So shares are getting locked up and the Market Makers want cheap shares that's why they are bringing it down on low volume . Metaverse is the new Bitcoin, get in early.
NEWS -- Provectus Biopharmaceuticals Announces Publication of Pharmaceutical-Grade Rose Bengal’s Activity Against Gram-Positive Bacteria
KNOXVILLE, TN, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on a formulation of the Company’s pharmaceutical-grade rose bengal against Gram-positive (G+) bacteria was published in Molecules, an open-access journal of chemistry.
The article, entitled “Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies,” may be accessed at: https://www.mdpi.com/1420-3049/27/1/322/htm.
This work, led by Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences, College of Pharmacy, was conducted under a sponsored research agreement between the University of Tennessee Health Science Center in Memphis, Tennessee and Provectus.
Dr. Kurosu and his colleagues showed that:
Tytan Cybernetics
@NIHKEV
·
2h
Great news. Thursday, 1/13/2022, there'll be an important special meeting for shareholders of $GMPW, $NIHK all the subsidiaries, which technically includes all the custodianships of @Alpharidge_Cap
. We have important updates about the business, M&A and Custos
NEWS -- Tokens.com’s Subsidiary, Metaverse Group, Partners with Decentraland to Launch Start-Up Competition
TORONTO, January 07, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in crypto assets linked to the Metaverse, Decentralized Finance ("DeFi"), and Non-Fungible Tokens ("NFTs") today announces that its subsidiary, Metaverse Group (https://metaversegroup.io/), has partnered with GDA Capital, RENOVI, and Decentraland to launch the first of its kind buildathon competition for architects, 3D designers and developers.
The start-up competition is encouraging university students, architects, and design professionals from around the world to create a variety of digital infrastructure including: buildings, museums, NFT galleries, casinos, and festival grounds. Participants will be competing for the opportunity to win a plot of land worth $250,000, granted by the Decentraland Foundation, $50,000 of RENOVI tokens, and software subscriptions to design tools such as Adobe and other key software programs.
The competition will be open to entries from January 30th until March 31st, 2022. The contest winners will be chosen by a panel of judges and sponsors who are leaders in the crypto and architectural industries. For full contest rules, details, and registration please visit https://topmetaversebuild.com/. All entries uploaded to the RENOVI marketplace will be available for sale, with proceeds going to contestants.
"We are excited to work with the next generation of students and architects to identify leading designs that can be displayed across Metaverses," commented Metaverse Group CEO, Lorne Sugarman.
"We are witnessing a Metaverse revolution that is going to be bigger than the dot.com boom or the Internet," said Michael Gord, GDA Capital Co-Founder. "This is a unique opportunity for early adopters to become part of modern history. The RENOVI marketplace is the perfect platform to showcase your metaverse build."
"This year has seen unprecedented growth in Decentraland and this competition is focused on ensuring this momentum continues in the new year and brings a large number of new builders to the metaverse," said Decentraland Community & Events Lead, Sam Hamilton. "We are thrilled to be working with GDA Capital, Renovi, Tokens.com and the Metaverse Group to provide resources that cultivate and nurture the next wave of eager blockchain developers, designers, and users."
Tokens.com is currently developing the Tokens.com Tower, in Decentraland’s Crypto Valley which will serve as an innovation hub with capabilities to host crypto conferences, events, and immersive experiences. The Tower will also hold office space for lease. The Tower is set to be completed in Q1 of 2022.
In addition, Metaverse Group has partnered with Decentraland to host the first of its kind, spring 2022 digital fashion show on its Fashion Street Estate which will feature avatar models, catwalks, pop-up shops, after parties, and immersive experiences connecting virtual to physical fashion from March 24th to 27th.
Tokens.com’s CEO, Andrew Kiguel has been featured in some of the worlds most prominent publications to discuss the metaverse including The Wall Street Journal, USA Today, and CNBC.
About Tokens.com
Tokens.com Corp is a publicly traded company that owns an inventory of Metaverse, DeFi and NFT based digital assets. Through a process called staking, Tokens.com’s inventory of crypto assets are used to earn additional tokens. In addition, Tokens.com is the majority owner of the Metaverse Group, one of the world’s first virtual real estate companies. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web 3.0.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
About GDA Capital
GDA Capital performs advisory services for digital asset companies, including go-to-market strategies, partnerships PR, community, tokenomics development. GDA Capital’s team has vast experience taking brand new technologies to market, as well as helping existing companies accelerate their growth. For more information please visit https://gda.capital/
About RENOVI
Launched in 2021, RENOVI is the first NFT marketplace created for architects, 3D designers and developers. NFTs within RENOVI can be used for artistic and collection purposes, with actual items also being made available to the metaverse. The secure platform has been developed by a team of senior leaders within the design, property, tech, finance and legal professions. https://www.renovi.io
About Decentraland
Decentraland is the first fully decentralized virtual world. Powered by DAO, which owns the most important smart contracts and assets of Decentraland. Decentraland is a software running on Ethereum that seeks to incentivize a global network of users to operate a shared virtual world. Decentraland users can buy and sell digital real estate, while exploring, interacting and playing games within this virtual world.
For further information please visit https://decentraland.org
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.io
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at https://www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005270/en/
Contacts
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Plus Therapeutics to Participate in Upcoming January Conferences
AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate at two virtual conferences in January.
Event: H.C. Wainwright BioConnect Conference
Date: January 10-13, 2022
Time: Presentation available on demand starting January 10 at 7:00 a.m. ET
Event: Biotech Showcase 2022
Date: January 10-12 & 17-19, 2022
Time Presentation available on demand
A webcast of the H.C. Wainwright presentation will be available under the ‘Events’ tab of the Investor Relations section of the Plus Therapeutics website at https://www.plustherapeutics.com. A webcast replay will be accessible for 90 days following the event.
Investors interested in arranging a virtual meeting with the Company’s management during the Biotech Showcase 2022 conference should contact the conference coordinator. The Company’s Biotech Showcase presentation can be accessed on demand to qualified investors through a complimentary registration on the conference website here: Biotech Showcase Registration (https://informaconnect.com/biotech-showcase/registration-options/).
About Plus Therapeutics
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it has entered into an agreement with The University of Texas Health Science Center at San Antonio (also referred to as UT Health San Antonio) for a worldwide exclusive license to develop and commercialize novel interventional therapeutics for cancer.
“The future of cancer therapy is precise targeting of tumors with the most potent cancer-killing agents while minimizing damage to normal tissues,” stated Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “Not only does this important transaction further expand our existing Rhenium NanoLiposome technology, but it also helps realize this future. With this technology, we can target almost any solid organ tumor in the body using standard interventional means to leverage the breadth of the human vascular system and deliver a resorbable biomaterial embolic technology coupled with a highly potent radiotherapeutic isotope.”
The licensed patents include composition of matter patents for biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or therapeutic payloads. Therapeutic payloads may include radiotherapeutics, chemotherapeutics or thermotherapeutics. The BAM technology is delivered into the vascular system via standard interventional vascular catheters that are placed precisely in the vessels feeding tumors. Once injected, BAM blocks all blood flow to the tumors and simultaneously delivers very high doses of cytotoxic compounds for an extended time. Many days later, the BAM resorbs and are physiologically metabolized and excreted from the body.
“Embolization technology for many types of tumors, including liver cancer, has been used with promising results for over two decades, but substantial limitations remain, and no meaningful recent technological innovations have been made,” said William Phillips, M.D., Professor of Nuclear Medicine at UT Health San Antonio. “The leading radioembolization therapies available today incorporate Yttrium-90 glass/resin microspheres which have poor imaging characteristics, require long lead times, are permanently implanted and may expose the marrow to high levels of radiation. Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) is a next generation, fully resorbable technology that solves many of the problems of existing technology. Our team at UT Health San Antonio intends to support Plus Therapeutics in bringing this technology rapidly to market.”
The financial terms of the exclusive license agreement are primarily success-based with milestone and royalty payments contingent on achieving key clinical, regulatory and sales milestones.
The Company will initially focus on developing 188RNL-BAM as a next-generation radioembolization therapy for liver cancer, in which BAM blocks the hepatic artery segments that supply blood to the malignant tumor while also providing 188RNL radiotherapy by directly irradiating the tumor.
“This transaction is the next step in our plan to expand our pipeline using precision, targeted radiotherapeutics,” said Norman LaFrance, M.D., Chief Medical Officer of Plus Therapeutics. “Next steps are to complete and compile the promising preclinical work performed thus far and prepare for an IND submission in 2022 for the treatment of liver cancer.”
Liver cancer is a rare disease with an increasing annual incidence and 5-year overall survival of only 20%1. The global opportunity for localized embolization, chemoembolization, and radioembolization therapies for primary (hepatocellular carcinoma) and secondary (typically metastatic colorectal cancer, for example) liver cancer is $1.3 billion2.
The initial inventions and work behind the licensed patents and technologies were developed and led by William Phillips M.D., Professor of Nuclear Medicine, Ryan Bitar, M.D., and their team at UT Health San Antonio. The 188RNL-BAM technology incorporates Rhenium-188, or 188Re, a very attractive isotope for use in radiotherapeutic embolization owing to its emission of a high energy electron (beta particle) with a half-life of 16.9 hours and a path length of 3.1 mm. 188Re emits gamma energy that permits high quality, real-time imaging of the BAM construct delivery localization and confirmation. 188RNL-BAM is straightforward and cost-effective to manufacture for on-demand availability for therapeutic applications and is versatile and can be precisely composed and manufactured to a specific size allowing optimal arterial embolization to block blood flow in most vascular beds while simultaneously delivering its isotopic payload to the tumor. BAMs are not permanent like other technology and degrade over time, allowing restoration of blood flow, decreasing radiation resistance, and allowing safer physiological and safe clearance of 188Re through the kidneys, which avoids bone marrow toxicity.
1American Cancer Society; 2Internal estimate
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics for adults and children worldwide with rare and difficult-to-treat cancers. Our proprietary radiotherapeutic platform uniquely uses nanoliposomes to encapsulate and deliver the radioisotope, Rhenium, into or near a tumor via a single, direct infusion. The lead radiotherapeutic in our pipeline, Rhenium-186 NanoLiposome (186RNL), is being evaluated in U.S. multi-center clinical trials for the treatment of recurrent glioblastoma and leptomeningeal metastases. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the future of cancer therapy; the potential promise of 186RNL and 188RNL-BAM including the ability of 186RNL and 188RNL-BAM to safely and effectively deliver radiation directly to the tumor at high doses; the help that the Company will receive from third parties in bringing its products to market; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL and 188RNL-BAM.
The forward-looking statements included in this press release are subject to several risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
You may be correct but that means it would have to hit 300 dollars a share and with a half-billion shares out it may take a while, whereas SMURF is a 2 dollar stock that has 75 million shares outstanding, and half of it is held by institutions and insiders and now owns a big piece of the metaverse .
RBLX is very expensive, I would think SMURF would have been a better investment than RBLX for a metaverse and token and NFT play.
This is being shorted like crazy !!!
NEWS -- Tokens.com to Host Decentraland’s Fashion Week
TORONTO, January 04, 2022--(BUSINESS WIRE)--Tokens.com Corp. (NEO Exchange Canada: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF) ("Tokens.com" or the "Company"), a publicly-traded company that invests in Web 3.0 assets linked to the Metaverse, Decentralized Finance ("DeFi"), and Non-Fungible Tokens ("NFTs") is pleased to announce that its subsidiary, Metaverse Group (https://metaversegroup.io/), has entered into a lease agreement with Decentraland to host its highly anticipated Fashion Week on its virtual property. The agreement allows Decentraland to develop Metaverse Group’s 116 parcel estate in the Fashion District, purchased in November 2021, with virtual towers, fashion tents and runways in preparation for the event.
The first of its kind virtual fashion event, being held March 24th to 27th, is expected to draw some of the biggest fashion brands in the world. Decentraland is partnering with Metaverse Group and UNXD to curate an exclusive fashion show experience featuring avatar models, catwalks, pop-up shops, after parties, and immersive experiences, connecting digital to physical fashion. The event aims to strengthen the fashion ecosystem in the metaverse, connecting communities, new designer brands and NFT projects.
"The metaverse is going to impact nearly every type of consumer technology including social media, gaming and fashion. Metaverse Group, our subsidiary, is at the forefront of this evolution. Our collaboration with Decentraland validates our thesis of becoming virtual landlords and being able to generate returns from our NFT properties through immersive experiences for users," commented Tokens.com CEO, Andrew Kiguel.
The fashion show partner UNXD is a luxury curated crypto marketplace that recently launched the Dolce & Gabbana NFT collection "Collezuone Genesi", which generated approximately $5.65 million in sales.
"We are excited to partner with Metaverse Group and Tokens.com on Fashion Week. Not only will this be the biggest event of its kind in Metaverse history, but this also validates the ability for Decentraland to create a fully functioning economy on an open virtual platform," said Sam Hamilton, Decentraland’s Community and Events Lead.
A metaverse is an online world where people can work, play games and communicate in a virtual environment. Tech firms have implemented metaverse elements in popular games including Animal Crossing, Fortnite and Roblox. These elements include planning live events such as concerts, fashion shows, conferences, pitch competitions and tournaments where millions of players can interact from around the globe.
2021 was a landmark year for luxury brand giants such as Gucci, Burberry, and Louis Vuitton who entered the metaverse through their designer NFTs. Through Metaverse Group, Tokens.com will be further developing Fashion Street and bringing new opportunities for fashion brands to showcase new digital merchandise in the metaverse.
Tokens.com has also solidified its presence through the Tokens.com Tower, which is currently under construction in Decentraland’s Crypto Valley and will be complete in Q1 2022. The tower will host future crypto conferences and events. The tower will also have leases, and will rent out virtual spaces to other companies. Since announcing the Tokens.com Tower several parties have expressed interest in renting out the spaces.
About Decentraland
Decentraland is the first fully decentralized virtual world. Powered by DAO, which owns the most important smart contracts and assets of Decentraland. Decentraland is a software running on Ethereum that seeks to incentivize a global network of users to operate a shared virtual world. Decentraland users can buy and sell digital real estate, while exploring, interacting and playing games within this virtual world.
For further information please visit https://decentraland.org
About Metaverse Group
The Metaverse Group is a vertically integrated NFT based metaverse real estate company. The group, with its global headquarters in Decentraland’s Crypto Valley, also owns an eight figure real estate portfolio across many leading virtual worlds. The company intends to continue to purchase, develop and rent out its portfolio of real estate assets. Tokens.com, a publicly- traded company, is the majority owner of Metaverse Group.
For further information please visit https://metaversegroup.io
About Tokens.com
Tokens.com Corp is a publicly traded company that owns an inventory of Metaverse, DeFi and NFT based digital assets. Through a process called staking, Tokens.com’s inventory of crypto assets are used to earn additional tokens. In addition, Tokens.com is the majority owner of the Metaverse Group, one of the world’s first virtual real estate companies. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web 3.0.
For further information please visit https://Tokens.com
Keep up-to-date on Tokens.com developments and join our online communities at Twitter, LinkedIn, and YouTube.
This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of cryptocurrencies, as described in more detail in our securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005646/en/
Contacts
For further information, please contact:
Tokens.com Corp.
Andrew Kiguel, CEO
Telephone: +1-647-578-7490
Email: mailto://contact@tokens.com
Jennifer Karkula, Head of Communications
Email: mailto://contact@tokens.com
Media Contact: Ryleigh Ebron – Talk Shop Media
Email: mailto://ryleigh@talkshopmedia.com
NEWS -- Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
CARLSBAD, Calif., January 04, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtual Conference (https://hcwevents.com/bioconnect/). The corporate presentation will be available to investors on demand, starting on January 10, 2022 at 7:00am ET on the Events and Presentations section of Lineage’s website (https://investor.lineagecell.com/events-and-presentations/upcoming-events).
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005219/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Mike Biega
(mailto://Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
NEWS -- Plus Therapeutics Announces Two Significant Milestones Toward cGMP Manufacture of its Lead Investigational Radiotherapeutic
WOW, that is a big model car !!!https://twitter.com/NIHKEV/status/1461032562256535556/photo/1
You hit the money , Frank said if he doesn't buy all the shares this year he will continue the next year 2022.
If you people would just follow Frank on Twitter , lawyers are working on Dividends and early 2022 will be released.
Well I think I know where Frank got the money to buy back shares and Metaverse property, a few months ago he had 44 shells , now he has 36 shells , 8 shells are sold or some transferred to new CEOs , heard VNTH is on a roll also, I own both NIHK and VNTH waiting for my DRNG dividends to come in 2022 . Good luck to all !!!
Starman2 thank you, I bought SMURF today because of your post, got 1000 shares at 1.92 .
Frank is buying today I predict 500,000 shares will be bought.
I think that NIHK could be more valuable than SMURF another metaverse play, also Tytan has the electric car deal and 44 shells that are worth tens of millions of dollars, plus the Tytan crypto coin for all green vehicles , so many irons in the fire to a profitable path in 2022 .
I think Frank is buying Metaverse land .
JM that is 1,175,574 shares bought by frank yesterday.
It's like getting in on the ground floor when bitcoin first came out , new ideas and new technologies will make the first people who act on them millionaires and the stockholders will prosper who hold them.
$NIHK seeks a driver-seat on this land-grab push -
— Tytan Cybernetics (@NIHKEV) December 22, 2021
Digital land is selling for millions as people scramble to snatch up virtual real estate in the metaverse—and it could be a multitrillion-dollar opportunity https://t.co/t64eyjFMiU @opportunityzon $META $NIHK $FB $NVDA $U $RBLX
NEWS -- Tytan Cybernetics (“Video River Networks” OTC) announces the Formation of Tytan Metaverse to Take Advantage of the Metaverse Properties Price-Discovery Opportunities.
TORRANCE, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Tytan Cybernetics/ Video River Networks “the Company” (OTC: NIHK TWTR: @NIHKEV), a technologically innovative holding company for Electric Vehicle, Fintech, Ai, Robotics, Drones, Distressed assets, and Business opportunities within the high growth, Fintech, Ai, Health, Sports and Entertainment industries, announces the formation of a wholly owned subsidiary, Tytan Metaverse to take advantage of the current Metaverse Properties price-discovery opportunities.
Tytan Metaverse seeks to become a Metaverse LANDLORD with holdings in Decentraland, Sandbox, Somnium Crytovoxels and Upland. Being a subsidiary of a successful real estate company, Tytan Metaverse plans to embark of rapid acquisitions of Metaverse properties, renting them out for income as well as holding them for long-term growth. Starting December 22, 2021, Tytan will dedicate staff and consultants to focus and comb through the Metaverse looking for property-bargains in Decentraland, Sandbox, Somnium Crytovoxels and Upland.
Tytan intends to acquire as many LAND blocks as it could lay its hands on before the end of 2021.
Tytan intend to start its search for lands in Sandbox. The Sandbox is a community-driven platform where creators can monetize voxel assets and gaming experiences on the blockchain. The Sandbox Metaverse comprises a map made up of 166,464 LANDS. LAND owners can host contests and events, stake (SAND) to earn and customize assets, monetize assets and experiences, vote in the Metaverse governance, play games that you or others create, and more.
The Metaverse continues to take the crypto world by storm with its amazing technology that enables users’ imagination to come to life. The Sandbox (SAND), a blockchain-based virtual network, looks like the go-to crypto space because of its aggressive performance in the market. In addition, the SAND network continues to develop its platform and provide new use cases to all its users in the network. SAND and other land developers are offering exclusive NFTs to all its community participants. These events can be a factor to be considered in the ever-growing ecosystem of the Sandbox.
About Tytan Cybernetics, Inc.
Tytan Cybernetics, Inc. is a holding company for a technologically innovative Electric Vehicle, Fintech, Ai, Robotics, Drones, Distressed assets, and Business opportunities within the high growth, Fintech, Ai, Health, Sports and Entertainment industries with focus to invest and bring to market the next generation of high-performance state-of-the-art products and services. The company’s current and expanding technology portfolio includes Electric Vehicles, Artificial Intelligence, Machine Learning and Robotics ("EV-AI-ML-R"), with businesses and operations in North America and Asia. With a commitment to revolutionary technology, Tytan Cybernetics is in the process of cultivating prosperous technologies to enhance consumer’s cybernetic experience.
For more information, please check the latest updates on the company's Twitter account https://twitter.com/NIHKEV
Notice Regarding Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
CONTACT:
Tytan Cybernetics/Video River Networks
370 Amapola Ave., Suite 200A
Torrance, CA 90501
mailto://contact@videorivernetworks.net
In the next 5 trading days, I would think that Frank would love the share price to fall so he can buy more cheap shares and spend less money in the process , I think he knows what he is doing, and the share price is ready to rock and roll , with great news in 2022.
You may be right but if there are just 5% weak hands that would be around 7 million shares for frank to buy .